• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Latest News

Talent Management Strategies for Post-Milestone Growth
Talent Management Strategies for Post-Milestone Growth

July 25th 2024

Insights from Takeda, Jazz, Nestlé Health Sciences, Humana, and other healthcare executives

Stock.adobe.com
Integrity Partners With Gosen Insurance Group to Bring New Solutions to Hispanic Communities in Florida

July 25th 2024

Rudy Kuhn
The Future of Digital Twins: Q&A with Rudy Kuhn

July 25th 2024

Sage and Biogen Halt Phase II Study After Novel Drug Shows No Significant Improvement in Treating Essential Tremor
Sage and Biogen Halt Phase II Study After Novel Drug Shows No Significant Improvement in Treating Essential Tremor

July 24th 2024

Mark Cuban Talks Drug Pricing: Pharm Exec Exclusive

Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur discusses the prescription drug cost landscape and shares his recipe for true disruption to the pharma pricing machine.

Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur discusses the prescription drug cost landscape and shares his recipe for true disruption to the pharma pricing machine.

Conference Coverage

View All
Sarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma
Sarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma

June 4th 2024

Moderna, Merck Present Promising Trial Data for a Combination of V940 with Keytruda for the Treatment of High-Risk Melanoma Following Complete Resection
Moderna, Merck Present Promising Trial Data for a Combination of V940 with Keytruda for the Treatment of High-Risk Melanoma Following Complete Resection

June 4th 2024

Phase III Trial Data Presented at ASCO Show Imfinzi Improves Survival in Limited-Stage Small Cell Lung Cancer
Phase III Trial Data Presented at ASCO Show Imfinzi Improves Survival in Limited-Stage Small Cell Lung Cancer

June 3rd 2024

Data Presented at ASCO Show Improved Complete Response with Jemperli as a First-Line Treatment for Locally Advanced Rectal Cancer in Patients with Mismatch Repair Deficient Status
Data Presented at ASCO Show Improved Complete Response with Jemperli as a First-Line Treatment for Locally Advanced Rectal Cancer in Patients with Mismatch Repair Deficient Status

June 3rd 2024

Latest Videos
Podcasts

All News